I am a board-certified Pediatric Gastroenterologist and Transplant Hepatologist and Section Chief of Hepatology and Transplant Medicine at Children's Mercy Hospital in Kansas City. I have a strong interest in translational research related to liver disease and transplantation, and novel therapeutics to treat disordered inflammation in the liver. My background in the lab includes basic research in dendritic cell biology, antigen presentation and cell-based immunotherapy.

Director, The Autoimmune and Rare Liver Disease Programme, and the Lily and Terry Horner Chair in Autoimmune Liver Disease Research, Division of Gastroenterology and Hepatology, Toronto General Hospital, Canada

I am a Hepatologist and Senior Clinical and Research Consultant at the Liver Disease and Hepatitis Program at the Alaska Native Medical Center in Anchorage, Alaska., an auxiliary professor at University of Alaska Health Sciences Program and Clinical Professor of Medicine at the University of Washington. I have directed the vaccination programs in Alaska Natives that reduced the prevalence of hepatitis B from the highest in the US to the lowest in the world.

Matthew D'Uva is the Chief Executive Officer (CEO) of the American Association for the Study of Liver Diseases (AASLD), the premier organization of health care professionals, researchers, and scientists committed to preventing and curing liver disease worldwide. Matthew also serves as CEO of AASLD Foundation, the philanthropic arm of AASLD committed to developing and supporting the hepatology workforce of the future.

In his role, Matthew oversees the implementation of AASLD's strategic plan, management of the organization's operations, and a team of nearly 50 professionals.

Dr. Trivedi is full professor at the National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre (BRC) in the UK. He is Chief Investigator for the UK-Primary Sclerosing Cholangitis (PSC) consortium, elected chair of the British Association for Study of the Liver Special Interest Group (BASL SIG) for immune-mediated and cholestatic liver disease, and steering committee member of the Global Primary Biliary Cholangitis (PBC) Group and International PSC Study Groups in 2022.

Dr. Hoofnagle served as the Director of Liver Disease Research Branch in the Division of Digestive Diseases and Nutrition for 23 years up until his retirement in 2026. He was active in liver disease research for over 50 years and has published more than 500 articles on topics in basic and clinical research on viral hepatitis, nonalcoholic fatty liver disease, acute liver failure, pediatric liver disease, cirrhosis, autoimmune liver diseases and drug-induced liver disease.

Dr. Carolyn Wester serves as the Director of the Division of Viral Hepatitis within CDC's National Center for HIV, Viral Hepatitis, STD, and TB Prevention. She has over 25 years of public health and clinical research experience focused on the prevention, diagnosis, and treatment of viral hepatitis, HIV, and STIs in the U.S. and internationally. In her current role, Dr.

Dr. Michelle Martin is a clinical pharmacist in the Liver Clinic at the University of Illinois Hospital and Health Sciences System (UI Health) where she has guided patients through hepatitis C virus (HCV) treatment since 2009. Physicians, physician assistants, and nurse practitioners refer all HCV patients to her to manage via her pharmacist-driven HCV management protocol.